도터, 생분해성스텐트(BRS) 임상 환자 모집 완료
생분해성스텐트(BRS) 임상 환자 128명 모집 완료.
고위험 동맥경화반의 분자적 특성을 밝히는 융합 영상기기 상용화로
110억원 규모 시리즈B 투자 유치 성공.
DOTTER is a globally patented technology-based healthcare company that provides solutions for diagnosing and treating lesions that cause ischemic heart disease.
As a company established by a combination of cardiovascular specialists and the best experts in Korea and the world in the field of optical coherence tomography (OCT), we are designing and producing sophisticated biodegradable stents (BRS) that are 30% thinner than its competitors. In addition, we are mainly developing next-generation OCT equipment, which is optical imaging equipment that can create a synergistic effect for stent insertion.
We aspire to diagnose and cure cardiovascular disease, the leading cause of mortality worldwide, using our unrivaled technological competitiveness, so that humankind can escape the pain of cardiovascular disease and enjoy a longer, healthier life.
Even now, while we pursue continuous technological innovation, we are focusing all our efforts and passion on ensuring the satisfaction of our customers and patients by prioritizing quality and safety.
Subscribe to our media mailing list and get updated with our most recent news
생분해성스텐트(BRS) 임상 환자 128명 모집 완료.
고위험 동맥경화반의 분자적 특성을 밝히는 융합 영상기기 상용화로
110억원 규모 시리즈B 투자 유치 성공.
Headquarter Insta-1 #315, 204 Convensia-daero, Yeonsu-gu, Incheon 22004, Korea
GMP site 1 #1004, 10F, Gasan Digital 1-ro 219, Geumcheon-gu, Seoul 08501, Korea
GMP site 2 A-911, 323 Incheon tower-daero, Yeonsu-gu, Incheon 22007, Korea
Research Lab #315, 23, Doho 1-gil, Samnam-eup, Ulju-gun, Ulsan, Korea
Sales Division #1302, 225, Gasan digital 1-ro, Geumcheon-gu, Seoul, Korea
Phone+82.32.721.6146
our Hours Mon-fri 10:00-18:00 (kST)
info@dotter.com